# AI Biologist - Gene Therapy Discovery at LatchBio

LatchBio is hiring an AI Biologist - Gene Therapy Discovery for a remote role open to applicants in United States. It pays $140k-$180k a year and Level rates it Works on AI ●●●○; you can [apply on LatchBio](https://jobsbylevel.com/go/88853171-e765-47f0-b218-25397ed9b410?utm_medium=ai-agent).

AI Level 3, AI centrality 75 out of 100. Remote (San Francisco (preferred)).

## Details

- Company: [LatchBio](https://jobsbylevel.com/companies/latchbio)
- AI level: AI Level 3 (score 75 out of 100)
- Location: Remote (San Francisco (preferred))
- Salary: $140k-$180k
- Posted: November 16, 2026
- Apply: https://jobsbylevel.com/go/88853171-e765-47f0-b218-25397ed9b410?utm_medium=ai-agent
- Free CV review for this job: https://jobsbylevel.com/cv-review?job=ai-biologist-gene-therapy-discovery-at-latchbio-e73337

## Prepare for this job

The job page lists 5 likely interview questions for this offer, with a CV checklist: https://jobsbylevel.com/jobs/ai-biologist-gene-therapy-discovery-at-latchbio-e73337

## Description

Latch builds rigorous scientific benchmarks ( benchmarks.bio ) for AI agents across biology. We work with frontier labs and pharma to measure whether agents can handle real biological workflows: the messy, multi-layer reasoning that matters in the field. We're seeking an AI Biologist to join our Gene Therapy Discovery team, pushing what AI can achieve in vector and payload design. About the Role You will be the scientific authority on ground truth, testing whether agents can reason like an expert gene therapy scientist. The data misleads constantly: a genome copy is not an expressed transgene, a titer is not an infectious unit, and enrichment in a library screen is not tropism. Knowing what the evidence actually supports is the work. You will build the tasks and datasets behind our benchmarks across AAV, lentiviral, and non-viral delivery, from target tissue to candidate nomination. Build the task Write gold-standard answers with the rationale an experienced vector scientist would defend. Design scenarios across the discovery arc: capsid or vector selection, promoter and regulatory element choice, payload design within packaging limits, transduction and expression, tropism, and early immunogenicity triage. Curate datasets from real programs: barcoded library NGS at DNA and RNA level, qPCR and ddPCR genome titers, capsid titers by ELISA or AUC, infectious unit assays, transduction across cell types and MOIs, payload expression, single-cell or spatial tropism, biodistribution, innate immune readouts. Build analysis pipelines in Python where useful, with tolerances that hold across replicates and analytical methods. Set the hard calls Catch the artifact. A variant enriched because it replicates or packages well, not because it transduces. DNA-level barcode recovery that counts uptake rather than completed transduction, so variants failing a late step still score. Barcode frequencies skewed by GC content, RT-PCR efficiency, or excess PCR cycles. An empty-to-full ratio that moves depending on whether it came from AUC, mass photometry, or a capsid-to-genome titer ratio, which overestimates empties. Partial genomes that count toward vector genome titer and read as infectious but add no potency. Transgene mRNA present with no detectable protein. Adjudicate conflicts. In vitro transduction against in vivo tropism. Weak bulk expression as inefficient delivery or as tight tropism for a rare cell type. A DNA-level transduction deficit against promoter silencing. Pre-existing neutralizing antibodies against intrinsic capsid performance. Then name the experiment that settles it. Weigh the tradeoffs. Tropism breadth versus specificity, expression level versus durability, payload size versus packaging capacity, promoter strength versus cell-type restriction, and when a potency gain costs immunogenicity or manufacturability. Judge the agent Interrogate reasoning step by step, and challenge conclusions that would not survive a project review. Pinpoint where agents go wrong: why the step fails, what an expert would do, what evidence would change the call. Score confidence, rewarding explicit uncertainty over overconfident calls on ambiguous data. Requirements PhD in molecular biology, virology, genetics, bioengineering, or a related field. An MS with equivalent hands-on program experience also qualifies. 2 to 6 years hands-on in gene therapy at a biotech or pharma, with your own analysis work in the last two years. You have personally generated or analyzed data that decided which vector, capsid, promoter, or payload advanced, and you can name the threshold and the call. Direct experience with at least one of: capsid or vector engineering and library screening, promoter and regulatory element design, transduction and expression assays, tropism or biodistribution analysis, or vector immunogenicity. Deep in one of those, fluent across the others. Strong experimental design, quantitative analysis, and statistics. AI-ready from day one: daily use of

The description is cut here. Read the full offer: https://jobsbylevel.com/jobs/ai-biologist-gene-therapy-discovery-at-latchbio-e73337

Source: https://jobsbylevel.com/jobs/ai-biologist-gene-therapy-discovery-at-latchbio-e73337

## Cite this page

Level. https://jobsbylevel.com/jobs/ai-biologist-gene-therapy-discovery-at-latchbio-e73337.

Get job alerts: https://jobsbylevel.com/newsletter
